100% Quality Guarantee
PhD-Level Technical Support
Anti-IL6R tocilizumab biosimilar mAb HDBS0041
Key Features

Tocilizumab Biosimilar (IL6R) Antibody (HDBS0041)

SKU HDBS0041
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein IL-6R
Reactivity Human
Host Species Humanized
Isotype IgG1
$569

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Tocilizumab Biosimilar (IL6R) Antibody (HDBS0041)

The IL6R (Tocilizumab) Biosimilar MAb (HDBS0041) is a monoclonal antibody designed for research involving Interleukin-6 Receptor (IL6R), a cell surface protein involved in immune responses and inflammation regulation. This biosimilar monoclonal antibody, similar to Tocilizumab, is highly reactive with human samples and is validated for use in various research applications, including ELISA and immunohistochemistry.IL6R is a critical receptor in the IL-6 signaling pathway, which plays a key role in regulating inflammation, immune responses, and acute phase reactions.

Targeting IL6R with monoclonal antibodies like Tocilizumab has shown promise in treating conditions such as rheumatoid arthritis, cytokine release syndrome, and other inflammatory disorders. The Anti-IL6R (Tocilizumab) Biosimilar MAb (HDBS0041) provides researchers with a valuable tool for studying the IL6R pathway and developing new therapies for inflammatory diseases.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose